The meta-analysis showed (Fig. 5) that immune checkpoint inhibitors versus chemotherapy had similar effects in treating NSCLC patients having EGFR mutation for the OS (HR, 1.11; 95% CI, 0.80–1.55). This evidence concerns the gene EGFR and non-small cell lung carcinoma.